Lysosome Biology Program
Neurodegenerative Diseases
PreclinicalActive
Key Facts
About Talisman Therapeutics
Talisman Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Cambridge, UK. It operates a dual business model, focusing internally on discovering novel therapeutics for neurodegenerative diseases while also providing access to its human iPSC-based neuroscience platform to external partners. The company's core strategy is to overcome the limitations of traditional neurological drug discovery by using human genetics-informed, stem cell-derived models to identify and validate new targets and drug candidates.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Modulo Bio | Discovery |
| PBI-01207 | Phoenix Biotechnology | Pre-clinical |
| Therapeutic Target Discovery Platform | ValtedSeq | Discovery |
| Undisclosed Neurology Program(s) | Base4 | Preclinical |
| Platform Application for Neurodegenerative Diseases | ALTUCELL | Pre-clinical/Research |
| OGG1 Activator Program | Luciole Pharmaceuticals | Pre-clinical |
| Microglial Health Program | Talisman Therapeutics | Preclinical |
| HSF1 Activator Program | Sisu Pharma | Pre-clinical |
| Platform-derived candidates | VRG Therapeutics | Pre-clinical |
| Neurodegenerative Biomarkers R&D | Firalis | Development |
| Neurodegeneration Pipeline | Origenis | Preclinical |
| Enhanced Brain Delivery (EBD™) Platform | Acumen Pharmaceuticals | Preclinical |